Compare Direxion Daily FTSE China Bull 3x Shares (YINN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily FTSE China Bull 3x Shares vs Zimmer Biomet Holdings Inc — how do they compare? Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 30.3× Direxion Daily FTSE China Bull 3x Shares's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Direxion Daily FTSE China Bull 3x Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily FTSE China Bull 3x Shares for 25 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| YINN | ZBH | |
|---|---|---|
Market Cap | $560.32M | $16.95B |
Volume | 1,009,521 | 2,505,240 |
Sector | Leveraged / Inverse | Health |
52-Week High | $52.69 | $103.98 |
52-Week Low | $21.45 | $79.58 |
Typical Hold Time | 25 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
YINN is trading at $25.27, up 7.26% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed fundamental ratios such as P/E and P/S, and recent news highlights China's economic policies and energy sector dynamics, which may influence its performance. Support is clustered around $23, with resistance at $24.
The outlook remains cautious due to bearish technicals and limited fundamental visibility. Risks include reliance on Chinese economic conditions and potential regulatory changes. Investment opportunities hinge on improved earnings transparency and positive shifts in market sentiment, but current data suggests a neutral to bearish stance for near-term investors.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
